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Anti-Mullerian hormone (AMH) is a protein that inhibits
the development of the mullerian ducts (paramesonephric
ducts) in the male embryo. AMH prevents the development
of the mullerian ducts into the uterus and other mullerian
structures in the first 8 weeks of gestational age. AMH is
produced by granulosa cells of the ovary during the repro-
ductive years and controls the formation of primary follicles
by inhibiting excessive follicular recruitment by FSH.
Whereas AMH is nearby undetectable in females at birth,
the level appears to be fairly stable in healthy young women
from puberty to the age of 30 years.
Some endocrine disorders are correlated with elevated
(PCOS) or lower AMH levels (premature ovarian insuffi-
ciency). Additionally some studies have shown that the dose
of stimulation in assisted reproduction therapy (ART) is
negatively correlated to serum AMH levels. Due to this asso-
ciation some authors stated that serumAMH reflects well the
ovarian follicular reserve.
The aim of the special issue is to summarize the actual
view and the clinical aspects of this interesting hormone in
different reproductive life stages.
The colleaguesN. Josso et al. andM. L. Johansen et al. give
an actual statement about the use of AMH in the pediatrics
endocrinology.
A. La Marca et al. have focused on the inter- and intrain-
dividual changes and especially the impact of ethnicity and
body mass index as well as smoking behaviours on the AMH
levels. They also highlight the impact of hormonal suppres-
sion of the ovarian function and its influence on the AMH
levels.
R. Tal and D. B Seifer give a review about the racial and
ethnical differences.
One manuscript deals with the usefulness of AMH in the
diagnosis of ovarian epithelial cancer. Another manuscript
describes the AMH levels as a possible marker of reproduc-
tive function after different cancers in young women after
chemotherapy.
Since AMH is also present in male, two manuscripts
have been selected concerning this topic: the paper by E.
Matuszczak et al. gives an overview about the physiology
and pathology of AMH levels in male and the second one,
written by R. P. Grinspon et al., deals with the AMH levels in
precocious puberty treated with GnRH.
We believe that AMH and it is clinical usefulness are a
topic that is of importance in scientific and clinical practice.
This special issue provides important facts and adds to the
actual discussion about the clinical usefulness of AMH. We
also appreciate gaining some overview about the meaning of
AMH in males.
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